BETA DRUGS LIMITED

BDL/PKL/SEC/2026-27
25th November, 2026

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400051

SYMBOL: BETA

Re:- Press Release Pursuant to Regulation 30 of Listing Regulations- Beta Drugs Limited receives COFEPRIS certification for select Oncology Products, reinforcing Its global quality credentials and strengthening its position in the high-growth Mexican Oncology market

Dear Madam/Sir

We are pleased to inform you that Beta Drugs Limited receives COFEPRIS certification for select Oncology Products, reinforcing Its global quality credentials and strengthening its position in the high-growth Mexican Oncology market.

Please find enclosed a copy of the press release being issued in this regard.

Kindly take the above information on record.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Beta Drugs Limited
Raju
Company Secretary
ACS - 24684

Rajni Brar
Company Secretary

P R E S S R E L E A S E

Beta Drugs Limited receives COFEPRIS certification for select Oncology Products, reinforcing Its global quality credentials and strengthening its position in the high-growth Mexican Oncology market

November 25, 2026, Panchkula — Beta Drugs Limited ("Beta" or "the Company") has received certification from Mexico's Federal Commission for the Protection against Sanitary Risks ("COFEPRIS") for select oncology products, including oral solid dosage forms and injectable formulations. The certification covers 48 oncology formulations including injectables, oral solids and oral suspensions. The certification paves the way for sales to commence from financial year ending 2027

COFEPRIS is Mexico's apex health regulatory authority, responsible for the sanitary registration and oversight of pharmaceutical products and is recognized by the Pan American Health Organization (PAHO/WHO) as a Level IV National Regulatory Authority — a distinction held by only a select group of regulatory agencies globally.

Commenting on the development, Mr. Rahul Batra, MD of Beta Drugs, said:

"Receiving the COFEPRIS certification is a significant milestone for Beta. It is a testament to our unwavering commitment to global quality standards. This certification validates the robustness of our quality systems, our manufacturing processes, and our ability to meet the stringent regulatory requirements of one of Latin America's most respected health authorities."

A Gateway to a Large and Fast-Growing Market

The certification positions Beta to address a significant share of Mexico's oncology pharmaceuticals market, which is valued at approximately USD 3.5 billion in 2025 and is projected to grow at a CAGR of approximately 10–11%. Mexico is the second largest pharmaceutical markets in Latin America, and oncology represents one of its fastest-growing therapeutic segments, driven by rising cancer incidence, expanding healthcare coverage, and an evolving regulatory environment that is increasingly supportive of high-quality generic and biosimilar products.

Reinforcing Beta's Credentials as a Global Partner of Choice

The COFEPRIS certification further strengthens Beta's growing roster of international regulatory approvals and reinforces its credentials as a reliable partner for global pharmaceutical collaboration. By demonstrating compliance with the high standards demanded by a PAHO/WHO Level IV regulatory authority, Beta enhances its attractiveness to multinational pharmaceutical companies, regional distributors, and institutional buyers seeking quality-assured oncology products from a dependable supply partner.

Varun Batra, Join MD, Beta Drugs added. *"This milestone is not just about market access — it is about trust. Every regulatory certification we earn reinforces the confidence that global partners, healthcare systems, and ultimately patients can place in Beta. We see this as a strong foundation for forging strategic alliances and deepening our presence across Latin America and other regulated markets worldwide. Mexico represents a compelling growth opportunity for our oncology portfolio. With this certification in hand, we are well-positioned to capture a meaningful share of this large and rapidly expanding market, while making quality oncology treatments more accessible to patients across the country,"*

About Beta Drugs Limited

Beta is a leading integrated oncology company with presence across branded formulations, CMO, exports and oncology APIs. Beta is among the largest suppliers of oncology formulations in India with a track record of supplying lifesaving critical oncology formulations to hospitals, marquee pharmaceutical companies and exporting them to regulated and semi-regulated markets

Safe Harbour Statement

Certain statements in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Beta Drugs undertakes no obligation to update or revise any forward-looking statements.